Administration of 500 mg/kg acetaminophen (APAP) to female B6C3F1 mice resulted in well-documented pathophysiological changes in the liver manifested as increased serum concentration of liver enzymes (aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, and serum sorbitol dehydrogenase), centrilobular congestion, and hepatocellular degeneration and necrosis. The role of proinflammatory cytokines, including tumor necrosis factor a (TNF-&alpha;) and interleukin 1&alpha; (IL-1&alpha;), on the hepatotoxicity of APAP was examined at 4,8, 12, and 24 hr following APAP administration. Neutralization of TNF-&alpha; or IL-1&alpha; with specific antibodies partially prevented the hepatotoxic effects of APAP at the 4and 8-hr time points. In addition, prior administration of anti-TNF-&alpha; antibodies shortened the recovery time following APAP treatment. While IL-1 receptor antagonist (IL-1ra) had only a modest protective effect against APAP-induced liver damage, as determined by serum enzyme release, IL-1ra had no effect on the degree of hepatic congestion or necrosis at any of the time points examined. On the other hand, administration of antibodies against IL-1ra exacerbated APAP-induced liver toxicity. These results suggest that TNF-&alpha; and IL-1&alpha; play an important role in the degree of damage and recovery that the liver undergoes following APAP intoxication.
INTRODUCTION
Acetaminophen (APAP) is a widely used analgesic and antipyretic drug with few side effects when taken at therapeutic doses. However, APAP intoxication can result in severe hepatic damage for which the mechanism has been well documented and characterized in both animals and humans (16, 25, 30) . The initial morphological changes in the liver following APAP overdose include glycogen loss and vacuolization of centrilobular hepatocytes, nuclear changes in many of the hepatocytes, and single-cell necrosis with pyknotic nuclei exhibiting eosinophilic degeneration (25) . At later time points, the centrilobular zones of severely damaged livers exhibit massive necrosis with confluent zones of anuclear, eosinophilic hepatocytes (25) . Much of this damage can be attributed to the active metabolite of APAP, N-acetyl-p-benzquinoneimine, which depletes cellular stores of glutathione and binds covalently to macromolecules resulting in eventual cell death (26) . In addition, the generation of reactive oxygen intermediates from within hepatocytes may also contribute to the hepatotoxicity of APAP (10, 14) .
Recently, the involvement of Kupffer cells (KCs) (18, 20, 21) and 2 proinflammatory mediators, tumor necrosis factor a (TNF-a) and interleukin 1 a (IL-1 a) (4), in APAP hepatotoxicity have been studied. Laskin et al (21) showed that hepatocytes treated with APAP release activating factors for KCs, which in turn are associated with areas of the liver that subsequently become necrotic (27) . TNF-a and IL-la are produced by activated KCs and, in addition to other products such as reactive oxygen, may have a central role in the inflammatory responses. Both cytokines have numerous biological effects and cellular targets, which include neutrophil and endothelial cell activation (6, 22) , promoting recruitment and adhesion of neutrophils to endothelial cells (12) and stimulating the production of additional cytokines and reactive oxygen intermediates (29) .
Recently, we have shown that TNF-a and IL-la are produced in response to APAP-induced damage and that selective neutralization of either of these cytokines alters the hepatic pathophysiological response to APAP intoxication (4) . The present investigation extends these studies by examining the role of APAP-induced cytokine production on liver morphology and liver-associated serum enzymes.
METHODS
Materials. APAP was obtained from Sigma (St. Louis, MO) and polyclonal antibody to murine IL-la was obtained from Genzyme (Cambridge, MA). Polyclonal antibody to murine TNF-a was prepared by injecting New (17) . Polyclonal antibody to human IL-1 receptor antagonist (IL-Ira) was obtained from R&D Systems (Minneapolis, MN). Recombinant IL-lra was the generous gift of Dr. James Vannice (Synergen, Inc., Boulder, CO). All other reagents used were of the highest purity available.
Animals. Female B6C3Fl (C57BL/6 X C3H) mice (Charles River Breeding Laboratories, Portage, MI), weighing 22-28 g and 80-100 days old, were housed in polycarbonate cages containing hardwood chip bedding at room temperature (21 ± 2°C) on a 12-hr light/dark cycle. Animals were provided rat chow (NIH31, Zeigler Bros., Inc., Gardner, PA) and tap water ad libitum throughout the study. Animals were assigned to groups randomly by weight prior to dosing such that there were no statistical differences between groups.
APAP administration. Animals were administered a single ip dose of 500 mg APAP/kg, dissolved in saline (pH 7.4). Control animals received a similar volume (10 ml/kg) of saline. Anti-TNF-oc (6 ml/kg), anti-IL-la (4 ml/ kg), and anti-IL-lra (4 ml/kg) antisera were administered immediately prior to APAP treatment by iv injection. Recombinant IL-1 ra was administered intravenously 30 min prior to APAP Euthanasia was performed by C02 as-phyxia using NIEHS-approved guidelines for the humane treatment of laboratory rodents. Serum Chemistry. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lactate dehydrogenase (LDH) were determined using an automatic chemical analyzer (15) . Serum sorbitol dehydrogenase (SDH) was determined as described by Gerlach and Hiby (13) .
Histopathology. The caudal portion of the left lobe from the liver of each mouse was removed and fixed by immersion in 10% neutral buffered formalin. Fixed tissues were embedded in paraffin, cut into 6-)JLm sections, and stained with hematoxylin and eosin for light microscopic examination. The following criteria were applied in grading the severity of the hepatic congestion or necrosis :
Grade 0: Normal histology. Grade 1: Characterized by minimal congestion and necrosis of single hepatocytes, limited to the area immediately around the centrilobular vein; many of the lobules not affected. Statistical Analysis. Comparisons involving more than 2 groups were analyzed by 1-way ANOVA. If a significant f-value occurred, the means were compared by Neuman-Keuls posthoc analysis (33) . In all statistical comparisons, a p-value of <0.05 was used to indicate a significant difference. All studies were conducted at least 3 times, and representative data are shown. Table I summarizes the changes in serum concentration of AST, ALT, LDH, and SDH in mice following administration of APAP and anti-TNF-a antibodies. Previously, TABLE IL-Effect of anti-TNF-a antibodies on hepatic congestion and necrosis following APAP administration.a -. H ..° Animals received 500 mg APAP/kg. Anti-TNF-a antibodies (6 ml/kg) were administered 30 min prior to APAP administration. The degree of congestion and necrosis were graded using the criteria described in the Methods section. 6 Values represent means ± SE, n = 8. III.-Effect of anti-IL-la antibodies on liver-associated serum enzyme levels following APAP administration.a a Animals received 500 mg APAP/kg. Anti-IL-la antibodies (4 ml/kg) were administered 30 min prior to APAP administration.
RESULTS

Effect of Anti-TNF-a Antibodies on APAP Hepatotoxicity
b Values represent means ± SE, n = 8. c Significantly lower than the APAP-treated animals at this time point (p < 0.05).
we showed that pretreatment of mice with anti-TNF-a antibodies was effective in preventing the increase in serum TNF-a following APAP treatment (4). Serum concentration of all enzymes increased sharply after APAP administration, reaching a peak at 12 hr. In the presence of anti-TNF-a antibodies, the increase in serum enzyme levels were partly, but significantly reduced at 4 and 8 hr, but not at 12 hr. Twenty-four hr following APAP treatment, the serum levels of AST, ALT, LDH, and SDH in mice pretreated with anti-TNF-a antibodies were approaching the levels observed in the anti-TNF-a-treated controls, whereas the enzyme levels in APAP-treated animals were 9, 17, 3, and 37 times higher, respectively, than that of the saline-treated controls.
The effect of anti-TNF-a antibodies on hepatic congestion and necrosis following APAP treatment is summarized in Table II . Administration of APAP resulted in necrosis and congestion of the hepatic sinusoids in the centrilobular and midzonal regions of the liver at the 4hr time point ( Fig. 1 A) . In contrast, pretreatment with anti-TNF-a antibodies limited the congestion to areas immediately adjacent to the centrilobular veins ( Fig. 1B) . However, at 12 hr the severity of the APAP-induced congestion was similar in the presence or absence of the anti-TNF-a antisera (Table II) . By 24 hr, much of the congestion had resolved in mice pretreated with anti-TNF-a, whereas minimal-moderate congestion (Grades 1-2) was still present in animals that had received APAP alone.
With the exception of the 12-hr time point, administration of anti-TNF-a antisera decreased the severity of necrosis present in the centrilobular regions.
Effect of Anti-IL-la Antibodies on APAP Hepatotoxicity
Treatment of mice with anti-IL-la antibodies prior to APAP administration partly prevented the increase in serum AST, ALT, LDH, and SDH at the 4and 8-hr time points (Table III) . Liver enzyme levels in APAP-treated animals in the presence or absence of anti-IL-la antibodies were similar after 12 hr. This occurred despite an 88% reduction in immunoreactive IL-la in the sera from mice pretreated with anti-IL-la antibodies 12 hr following APAP administration (4) . The severity of the APAPinduced hepatic congestion was maximal at the 4-hr time point (Table IV) . Preadministration of anti-IL-la antibodies did not significantly reduce the severity of the hepatic congestion observed at the 4-hr time point. However, in the presence of the antibodies, congestion was reduced by as much as 71 and 69% at the 8-and 12-hr time points, respectively (Table IV) . Following APAP administration, centrilobular necrosis was present in all livers and increased in severity over time independent of anti-IL-la antibody treatment. In the presence of anti-ILla antibodies, the APAP-induced necrosis was reduced in severity at all time points examined, though this difference was not statistically significant at the 12and 24hr time points (Table IV) Effect of IL-1 ra on APAP Hepatotoxicity Table V summarizes the changes in liver-associated serum enzyme levels following administration of APAP in the presence or absence of IL-lra. Animals treated with a combination of IL-lra and APAP had serum concentrations of AST, ALT, LDH, and SDH that were reduced by as much as 47, 27, 31, and 49%, respectively, at the 4-hr time point when compared to animals treated with only APAP and remained significantly lower at 8 hr. However, at 12 and 24 hr following APAP administration, the serum enzyme concentrations were similar in the presence or absence of IL-lra. Administration of IL-lra prior to APAP did not significantly reduce the degree of hepatic congestion or necrosis following APAP treatment TABLE IV.-Effect of anti-IL-la antibodies on hepatic congestion and necrosis following APAP administration.a a a Animals received 500 mg APAP/kg. Anti-IL-la antibodies (4 mllkg) were administered 30 min prior to APAP administration. The degree of congestion and necrosis were graded using the criteria described in the Methods section. b Values represent means ± SE, n -8. 1 Significantly lower than the APAP-treated animals at this time point (p < 0.05). at any of the time points studied (Table VI) . However, the average severity grade for the necrosis present at each time point studied tended to be lower. No significant differences in hepatic morphology were observed in the APAP-treated mice in the presence or absence of IL-lra.
Effect of Anti-IL-lra Antibodies on APAP Hepatotoxicity
Compared to mice treated with only APAP, the administration of anti-IL-lra antibodies prior to APAP increased the serum concentrations of AST, ALT, SDH, and LDH by 1.67-, 2.3-, 2.88-, and 4-fold, respectively (Table   VII ). With the exception of LDH, the serum enzyme concentration in animals treated with anti-IL-lra alone were similar to that of the saline-treated controls. Compared to the saline-treated controls, administration of anti-IL-lra antibodies had no visible effect on liver morphology (data not shown). However, administration of anti-IL-lra antibodies exacerbated the APAP-induced liver damage (Fig. 3B ). The necrosis observed in animals dosed with both APAP and anti-IL-1 ra was more widespread (Grade 2) as compared to the liver damage in mice dosed with APAP only (Grade 1). Although anti-IL-lra antibodies had little effect in reducing hepatic congestion from APAP administration, the severity of the coagulative necrosis present at 8 hr was significantly greater (Table   VIII) . (25) . Furthermore, Laskin (18, 19) has ' suggested that the development of APAP-induced centrilobular necrosis is the result of the interaction between the parenchymal and nonparenchymal cells. Nonparen-L chymal cells, such as KCs in addition to serving as a _ source of chemotactic factors and generating reactive ox-, ygen intermediates, are capable of producing a number ' of proinflammatory mediators responsible for the hepatic ' acute phase response (2, 32) . Recently, we have shown that two proinflammatory cytokines, TNF-a and IL-la, are produced in the liver in response to APAP (4). The _ present study demonstrates that TNF-a and IL-la play _ an important role in modulating APAP-induced liver j damage. Altering the actions of either of these cytokines , by increasing or decreasing their levels by specific modl ulators can suppress or enhance the severity of these effects. Previously, we have shown that decreasing the se-, rum concentration of TNF-a or IL-la reduces several l pathophysiological responses associated with APAP toxj icity including the release of hepatic enzymes and . changes in body temperature, whereas increasing the serum levels of IL-la increases these responses (4) . j Overproduction of TNF-a and IL-1 a has been associ-; ated with a number of clinical conditions, such as alcoj holic hepatitis (3) , fulminant liver failure (28), and cir-; rhosis (23) . In addition, both cytokines cause a variety of L pathophysiological conditions in the liver, including the increased expression of adhesion molecules on endothe-; lial cells (34), migration and activation of neutrophils (11) , increased cellular cytotoxicity (5) , enhanced syn-TABLE VL-Effect of IL-lra on hepatic congestion and necrosis following APAP administration., a Animals received 500 mg APAP/kg. IL-lra protein (7.5 mg/kg) was administered 30 min prior to APAP administration. The degree of congestion and necrosis were graded using the criteria described in the Methods section. ' Severity score was significantly higher than APAP-treated animals (p < 0.05). thesis of matrix proteins (7) , and hemorrhagic necrosis and tissue remodeling (35) .
In agreement with our observation that the administration of antibodies against TNF-a delayed and lessened the severity of the hepatic congestion following APAP intoxication, Van der Poll et al (36) showed that TNF is an important activator of blood coagulation in septicemia. However, the presence of the TNF-a antibody did not prevent the eventual increase in hepatic congestion and subsequent necrosis. A possible explanation is that other cytokines and cellular factors, with actions similar to that of TNF-a, are produced and released as part of an inflammatory response (1) and that these cytokines can initiate many of the observed pathological changes associated with TNF-a.
IL-1 a, like TNF-a, appears to play an important role in the hepatotoxic response to APAR Lowering the serum levels of IL-1 a through the administration of specific antibodies or receptor antagonist had a partial, but significant, hepatoprotective effect, whereas increasing circulating IL-la concentration exacerbated the resultant damage as evidenced by the severity of the necrosis and the presence of liver enzymes in the serum. Prior treatment with anti-IL-1 a or IL-1 ra did not prevent the occurrence of congestion or necrosis caused by the APAP treatment.
However, in the presence of either anti-IL-1 a or IL-1 ra, APAP-induced liver damage was either reduced or resolved in a shorter period of time. The ability of the anti-IL-1 a antibodies or IL-1 ra to moderate APAP-induced hepatotoxicity is likely related to their inherent effectiveness in blocking IL-1-induced biological responses. In this respect, a number of inflammatory diseases including rheumatoid arthritis and inflammatory bowel disease can be modulated experimentally by IL-lra (8) . In this study, prior administration of anti-IL-la was more effective in suppressing serum IL-1 levels and liver enzyme release than the administration of IL-1 ra. A likely explanation for this difference is that while antibodies neutralize IL-1 before it can bind to its receptors, IL-lra does not affect the activity of IL-1. Rather, IL-1 ra must be present in high concentrations in order to competitively block IL-1 from binding to its receptors in order to inhibit its biological effect (9) . Because the binding of IL-lra to the receptor is reversible, as much as a 100-fold excess is required to maintain an effective blockade (24) . As the mice in our study were pretreated with a single dose of IL-lra, it is possible that the concentration of IL-lra needed to produce a complete blockade of IL-1 receptors was not maintained over time. The importance of IL-lra in controlling the IL-1-induced biological response was apparent in animals dosed with the anti-IL-lra antibody. Neutralization of the naturally occurring IL-lra enhanced the hepatotoxic effects associated with elevated IL-1 levels. To this end, prior administration of anti-IL-lra antibodies significantly increased the severity of hepatic necrosis and the release of liver enzymes (AST and SDH) as compared to animals that received only APAP It was noted that hepatic damage and repair, as observed morphologically, occurred at a slightly different time than that observed for the increase in liver enzymes.
Based on the enzyme data, treatment with either anti-IL-1 a or IL-1 ra had a protective effect during the first 8 hr after treatment, whereas histological examination of the same livers indicated morphological differences between the APAP treated and APAP/anti-IL-la treated, but not APAP/IL-lra treated mice at the later time points. This is in agreement with Poulsen et al (31) , who observed that different functions of the liver are unequally influenced following APAP administration and that functional changes precede morphological alterations. We conclude that changes in serum enzyme concentrations provide a more sensitive marker of initial hepatic damage than morphological examination, whereas the latter can better assess the recovery through the examination of changes in vascular congestion and hepatocellular necrosis.
In summary, these studies demonstrate that the development and resolution of APAP-induced liver toxicity is partially mediated by TNF-a and IL-I&OElig; and support previous findings that APAP-induced hepatotoxicity results from the interaction between parenchymal and nonparenchymal cells. As these studies examined only the actions of individual cytokines, rather than the enhanced or suppressed responses of various cytokine combinations, further studies are needed to determine the role of cytokine synergism in this process.
